Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 2/20 | 0.66 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168485 | 0.90 | CASR (0.68) | CASRROCK2ROCK1MAPTELOVL1 | |
| SCHEMBL2466739 | 0.88 | CASR (0.70) | CASRROCK2ROCK1MAPTELOVL1 | |
| SCHEMBL2434872 | 0.85 | CASR (0.67) | CASRROCK2ROCK1MAPTELOVL1 | |
| SCHEMBL2437673 | 0.84 | CASR (0.63) | CASRROCK2ROCK1MAPTELOVL1 | |
| SCHEMBL12329228 | 0.83 | CASR (0.65) | CASRROCK2ROCK1MAPTELOVL1 | |
| SCHEMBL2431978 | 0.83 | CASR (0.62) | CASRROCK2ROCK1MAPTELOVL1 | |
| SCHEMBL3636579 | 0.83 | ROCK2 (0.63) | CASRROCK2ROCK1MAPTELOVL1 | |
| SCHEMBL2436404 | 0.82 | CASR (0.59) | CASRROCK2ROCK1MAPTPARP1 | |
| SCHEMBL12434049 | 0.82 | CASR (0.59) | CASRROCK2ROCK1MAPTRAB9A | |
| SCHEMBL2317588 | 0.81 | CASR (0.83) | CASRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SASU (FR) | 2012-11-08 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| US-8247412-B2 | Urea derivatives methods for their manufacture and uses thereof | GALAPAGOS SASU (FR) | 2012-08-21 | — | — | US | disclosed |
| EP-1874765-B1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE AND USES THEREOF | GALAPAGOS SAS (FR) | 2012-03-07 | — | — | EP | disclosed |
| EP-2354137-A1 | Urea derivatives, methods for their manufacture, and uses thereof | Galapagos SAS (FR) | 2011-08-10 | — | — | EP | disclosed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | disclosed |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | PROSKELIA SAS (FR) | 2010-09-23 | — | — | US | disclosed |
| EP-1874765-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | Proskelia SAS (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006117211-A2 | UREA DERIVATIVES METHODS FOR THEIR MANUFACTURE AND USES THEREOF | PROSKELIA SAS (FR) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283255-A1 | UREA DERIVATIVES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | UTS2R, UGP2, SLC14A1 | CASR 4125/4885ROCK2 1702/4885ROCK1 918/4885 |
| US-20100240889-A1 | Urea Derivatives Methods For Their Manufacture And Uses Thereof | UGP2, UTS2R, UMPS | CASR 4045/4885ROCK2 2137/4885ROCK1 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.